Associated Press - Thursday February 22, 2001
The new vaccine has been able to prevent laboratory monkeys exposed to an extremely virulent strain of the disease from contracting it, sources close to the trials told the Journal. This has AIDS scientists watching the results of the trials very closely.
The company would not discuss the details of the laboratory trials, but did say it began testing the vaccine in healthy, uninfected volunteers last week.
The drug is not the first possible vaccine to go into human trials. At least a dozen other companies are currently experimenting with a possible vaccine, but scientists familiar with the Merck trials say that their drug is among the most promising.
Merck official said they were reluctant to release any details regarding the trials before making a formal presentation at a scientific forum in April, lest publicity raise false hopes.
010222
AP010218
Copyright © 2001 - Associated Press. Reproduction of this article (other than one copy for personal reference) must be cleared through the AP Permissions Desk.
ÆGIS is made possible through unrestricted grants from Boehringer Ingelheim, iMetrikus, Inc., John M. Lloyd Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2001. This material is designed to support, not replace, the relationship that exists between you and your doctor.
ÆGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2001. ÆGIS. All materials appearing on ÆGIS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of ÆGIS, or the party credited as the provider of the content. Feedback/Contact Us.